Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

Stock Information for Y-mAbs Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Y-mAbs Therapeutics Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNT, DAY, WOW, YMAB on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DAY, WOW, YMAB, STAA on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Dayforce, Inc. (NYSE- DAY), WideOpenWest, Inc. (NYSE - WOW), STAAR Surgical Company (Nasdaq - STAA), Y-mAbs Therapeutics, Inc. (Nasdaq - YMAB)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VBTX, TASK, YMAB on Behalf of Shareholders
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNOW, TASK, YMAB on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger of DNOW, TASK, SQCF, and YMAB
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, DNOW on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.